Olympus (TSE:7733) is back in the spotlight after the U.S. launch of its VISERA ELITE III surgical imaging platform, a multi-specialty system that combines True 4K, 3D imaging, and software-driven workflow tools.

See our latest analysis for Olympus.

Despite the VISERA ELITE III launch putting Olympus back on investors' radar, the 1-day and 7-day share price returns of 2.25% and 4.45% sit against a weaker backdrop, with a 90-day share price return of a 28.84% decline and a 1-year total shareholder return of a 30.00% decline suggesting recent momentum has been fading.

If this kind of medical technology story interests you, it may be worth widening your search with a screener focused on healthcare related AI names such as 7 healthcare AI stocks.

With the shares showing sizeable 1 year and 3 year total return declines despite steady revenue and net income growth, and trading at roughly a 15% discount to one intrinsic value estimate, is Olympus a mispriced opportunity, or is the market already factoring in expectations for future growth?

Most Popular Narrative: 25.4% Undervalued

Olympus last closed at ¥1,408, while the most followed narrative estimates fair value at ¥1,888.46, putting a sizeable gap between market price and modelled worth.

The reorganization into more customer-focused divisions, including the creation of the Gastrointestinal Solutions Division (GIS) and the Surgical and Interventional Solutions Division (SIS), is expected to improve efficiency and execution. This change aims to drive market penetration and unlock recurring revenue streams, positively impacting revenue and net margins.

Read the complete narrative.

Want to see what is really backing that valuation gap? Revenue, earnings, margins, and the future P/E are all wired into this story. The mix may surprise you.

Result: Fair Value of ¥1,888.46 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this story can still be knocked off course if China revenue pressure persists or if high R&D spending weighs on margins longer than analysts expect.

Find out about the key risks to this Olympus narrative.

Next Steps

If this mix of potential and risk leaves you unsure, now is a good time to review the data yourself and stress test the optimism around the story by checking the 4 key rewards.

Looking for more investment ideas?

If Olympus has caught your attention, do not stop there. Use a few focused stock lists to spot other opportunities that match your style and risk tolerance.

• Target potential mispricings by scanning 21 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Prioritize resilience by checking 47 resilient stocks with low risk scores where companies score strongly on stability and downside protection.
• Get ahead of the crowd by reviewing a screener containing 58 high quality undiscovered gems before they land on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.